Recent Finacing
Recent Raise
Bright Peak Therapeutics develops chemically synthesized, site-specifically conjugated cytokine-based immunotherapies using an EDC chemical protein synthesis and conjugation platform, advancing IL-2, IL-18 and IL-7 immunocytokine programs into clinical development.
